ArticleBiochemical genetics2026
Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) treatment with imatinib mesylate often faces challenges due to inter-patient variability in drug response and adverse effects. Genetic polymorphisms in enzymes involved in imatinib metabolism, such as CYP2C8 and CYP3A4, may contribute to this variability. This study aimed to investigate the distribution of CYP2C8*3, CYP2C8*4, and CYP3A4*22 among CML patients and evaluate their impact on imatinib exposure and side effects. A descriptive cross-sectional study was conducted on Palestinian CML patients receiving 400 mg daily imatinib between June 2021 and August 2022. Genetic analysis and plasma imatinib levels were determined, along with assessment of demographic and clinical parameters. Results revealed significant associations between CYP2C8*3 genotype and lower imatinib trough concentrations, while CYP2C8*4 and CYP3A4*22 variants showed no significant effects. Imatinib C
Indexed as
Identifiers
40355686What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.